. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Immunol Cell Biol. 2014 Nov 4;93(3):290–296. doi: 10.1038/icb.2014.93

Table 1.

BiTEs in clinical and preclinical assessment

Target	Name	Target Disease	Clinical Status	References
CD19	Blinatumomab/MT-103/MEDI-538	NHL, ALL	Phase I/II/III	^{13, 28, 32, 33, 40, 41}
EpCAM	MT110	Solid tumors	Phase I	^{22, 26, 27, 43}
CEA	MT111/MEDI-565	GI adenocarcinoma	Phase I	^{12, 15}
PSMA	BAY2010112/AMG112	Prostate	Phase I	²⁵
CD33		AML	Preclinical	^{49, 50}
EGFR		Colorectal cancer	Preclinical	¹⁶
Her2			Preclinical	⁴⁶
EphA2	bscEphA2xCD3	Multiple solid tumors	Preclinical	³⁸
MCSP	MCSP-BiTE	Melanoma	Preclinical	¹⁷
ADAM17	A300E	Prostate cancer	Preclinical	³⁹
PSCA		Prostate cancer	Preclinical	²⁴
17-A1			Preclinical	²³
NKG2D ligands		Multiple solid and liquid tumors	Preclinical	⁴⁸